Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
Completed · Phase 2 · NCT06251024
Conditions: Respiratory Syncytial Virus Infection, Healthy Volunteers
At a glance
- Research payments reported, 2025
- $11,500
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 4,541
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- RSV vaccine candidate (biological), Placebo (biological)
- Dates
- Started 2024-04-02; completion 2025-03-11
- Results posted
- Not yet
The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV. The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-muscular (IM) administration of either a pre-determined dose of the RSV vaccine candidate or placebo.
From ClinicalTrials.gov, last updated 2026-03-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $11,500 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.